Cladribine for multiple sclerosis: review and current status

References

• Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc. Natl Acad. Sci. 81, 2232–2236 (1984).
   PubMed Web of Science ®Google Scholar
• Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340, 952–956 (1992).
   PubMed Web of Science ®Google Scholar
• Beutler E, Carson DA. 2-Chlorodeoxyadenosine: hairy cell leukemia takes a surprising turn. Blood Cells 19, 559–568 (1993).
   PubMedGoogle Scholar
• Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin. Hematol. 31, 40–45 (1994).
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 13, 570–574 (1995).
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD, Lemon RH. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73, 2953–2963 (1994).
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72, 1069–1073 (1988).
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117–1121 (1990).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 11, 679–689 (1993).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Heldal D, Hippe E . Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 13, 989–995 (1995).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Martinsson U, Cavallin-Stahl E . Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 30, 573–581 (1998).
   PubMed Web of Science ®Google Scholar
• Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80, 587–592 (1992).
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD. 2-chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol. Cell Ther. 38(Suppl. 2), S93–S101 (1996).
   PubMedGoogle Scholar
• Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 14, 2139–2144 (1996).
   PubMed Web of Science ®Google Scholar
• Figueroa M, McMillan R. 2-chlorodeoxyadenosine in the treatment of chronic refractory immune thrombocytopenic purpura. Blood 81, 3484–3485 (1993).
   PubMed Web of Science ®Google Scholar
• Eibschutz B, Baird SM, Weisman MH. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Arthritis Rheum. 38, 1604–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Petroutsos G, Moutsopoulos HM, Skopouli FN. 2-chloro-2'-deoxyadenosine in the treatment of Sjogren's syndrome-associated B cell lymphoproliferation. Arthritis Rheum. 46, 2248–2249 (2002).
   PubMed Web of Science ®Google Scholar
• Merkel PA, Letourneau EN, Polisson RP. Investigational agents for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21, 779–796 (1995).
   PubMed Web of Science ®Google Scholar
• Beutler E, Carson D, Sipe JC et al. 2-chlorodeoxyadenosine in nonmalignant disorders. In: Nucleoside Analogues in Cancer Therapy. Marcel Dekker, Inc., NY, USA, 359–382 (1997).
   Google Scholar
• Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067–1069 (1972).
   PubMed Web of Science ®Google Scholar
• Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl Acad. Sci. 74, 5677–5681 (1977).
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Kaye J. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. 77, 6865–6869 (1980).
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62, 737–743 (1983).
   PubMed Web of Science ®Google Scholar
• Liliemark J. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet. 32, 120–131 (1997).
   PubMed Web of Science ®Google Scholar
• Tortorella C, Rovaris M, Filippi M. Cladribine. Ortho Biotech Inc. Curr. Opin. Investig. Drugs 2, 1751–1756 (2001).
   PubMedGoogle Scholar
• Carson DA, Seto S, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism, and programmed cell death. Exp. Cell Res. 164, 273–281 (1986).
   PubMed Web of Science ®Google Scholar
• Seto S, Carrera CJ, Wasson DB, Carson DA. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J. Immunol. 136, 2839–2843 (1986).
   PubMed Web of Science ®Google Scholar
• Seto S, Carrera CJ, Wasson DB, Carson DA. Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes. Adv. Exp. Med. Biol. 195(Pt B), 577–582 (1986).
   PubMedGoogle Scholar
• Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ. Marrow suppression produced by repeated doses of cladribine. Acta Haematol. 91, 10–15 (1994).
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl Acad. Sci. 93, 1716–1720 (1996).
   PubMed Web of Science ®Google Scholar
• Selby R, Brandwein J, O'Connor P. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can. J. Neurol. Sci. 25, 295–299 (1998).
   PubMed Web of Science ®Google Scholar
• Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 128, 1747–1763 (2005).
   PubMed Web of Science ®Google Scholar
• Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv. Exp. Med. Biol. 309A, 15–18 (1991).
   PubMedGoogle Scholar
• Saven A, Kawasaki H, Carrera CJ. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol. 11, 671–678 (1993).
   PubMed Web of Science ®Google Scholar
• Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Res. 51, 5570–5572 (1991).
   Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 10, 1514–1518 (1992).
   PubMed Web of Science ®Google Scholar
• Grieb P, Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Arch. Immunol. Ther. Exp. 43, 323–327 (1995).
   PubMedGoogle Scholar
• Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111, 35–44 (1999).
   PubMedGoogle Scholar
• Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin. Hematol. 33, 45–52 (1996).
   PubMed Web of Science ®Google Scholar
• Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344, 9–13 (1994).
   PubMed Web of Science ®Google Scholar
• Serono Press Release. Serono and IVAX to initiate phase III clinical trial of Mylinax in multiple sclerosis. 1–11–2005.
   Google Scholar
• Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 13, 2431–2448 (1995).
   PubMed Web of Science ®Google Scholar
• Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34, 1368–1372 (1984).
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54, 1145–1155 (2000).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55, 1714–1718 (2000).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Rice GP. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J. Neurol. Sci. 176, 42–44 (2000).
   PubMed Web of Science ®Google Scholar
• Adams HP, Wagner S, Sobel DF. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur. Neurol. 42, 52–63 (1999).
   PubMed Web of Science ®Google Scholar
• Koziol JA, Frutos A, Sipe JC, Romine JS, Beutler E. A comparison of two neurologic scoring instruments for multiple sclerosis. J. Neurol. 243, 209–213 (1996).
   PubMed Web of Science ®Google Scholar
• Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 18, 53–63 (1999).
   PubMed Web of Science ®Google Scholar
• Beutler E, Koziol JA. The cladribine trial in secondary progressive multiple sclerosis: a reanalysis. Neuroepidemiology 19, 109–112 (2000).
   PubMed Web of Science ®Google Scholar
• Goodin DS. The cladribine trial in secondary progressive MS: response. Neuroepidemiology 19, 53–54 (2000).
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Stelmasiak Z, Mitosek-Szewczyk K, Belniak-Legiec E, Dobosz B. The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine). Ann. Univ. Mariae Curie Sklodowska (Med) 55, 231–234 (2000).
   Google Scholar
• Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing–remitting multiple sclerosis (RR–MS) treated with cladribine. Acta Neurol. Scand. 109, 390–392 (2004).
   PubMed Web of Science ®Google Scholar
• Niezgoda A, Losy J, Mehta PD. Effect of cladribine treatment on β-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol. 60, 225–228 (2001).
   PubMedGoogle Scholar